If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Guglielmo Nasti is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 31 Similar Profiles
Colorectal Neoplasms Medicine & Life Sciences
oxaliplatin Medicine & Life Sciences
irinotecan Medicine & Life Sciences
Drug Therapy Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
HIV Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
Disease-Free Survival Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 1994 2019

1 Citation (Scopus)
Open Access
irinotecan
Antibody-Dependent Cell Cytotoxicity
Colorectal Neoplasms
oxaliplatin
Therapeutics

Discontinuation of first-line bevacizumab in metastatic colorectal cancer: the BEAWARE Italian Observational Study

Lonardi, S., Nasti, G., Fagnani, D., Gemma, D., Ciuffreda, L., Granetto, C., Lucchesi, S., Ballestrero, A., Biglietto, M., Proserpio, I., Bergamo, F., Proietti, E. & Tonini, G., Jun 1 2019, In : Tumori. 105, 3, p. 243-252 10 p.

Research output: Contribution to journalArticle

Observational Studies
Colorectal Neoplasms
Drug-Related Side Effects and Adverse Reactions
Disease-Free Survival
Italy

Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC)

Berretta, M., Cobellis, G., Franco, R., Panarese, I., Rinaldi, B., Nasti, G., Francia, R. D. I. & Rinaldi, L., Jan 1 2019, In : European Review for Medical and Pharmacological Sciences. 23, 22, p. 10139-10150 12 p.

Research output: Contribution to journalArticle

Open Access
Colorectal Neoplasms
Therapeutics
aflibercept
Bevacizumab
Survival